USPTO serial 79339491
Serial No. 79339491
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 25, 2023
- Examiner
- DUBIN, DAVID I
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Serial No. 79339491?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maury M. Tepper, III
Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRRALEIGH, NC 27609UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Anti-infectives; Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations, namely, pharmaceutical preparations for use in dermatology; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma, all the foregoing specifically excluding dermatological products and preparations, injectable pharmaceuticals for dermatological use, injectable dermal fillers, medicated creams and pharmacological preparations for skin care | ACTIVE | — |
| 010 | Medical apparatus and instruments for diagnosing and treating cardiovascular diseases; Medical apparatus and instruments for diagnosing and treating dermatological diseases; medical apparatus and instruments for diagnosing and treating respiratory diseases and disorders; medical apparatus and instruments for diagnosing and treating central nervous system diseases; medical apparatus and instruments for the diagnosis and treatment of gastro-intestinal diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; medical apparatus and instruments for use in hematology and in tissue and organ transplantation; medical apparatus and instruments for the diagnosis, prevention and treatment of eye diseases and conditions; medical apparatus and instruments for the diagnosis, prevention and treatment of heart rhythm disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of immune system related diseases and disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of kidney diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of diabetes; medical apparatus and instruments for the diagnosis, prevention and treatment of hypertension; medical apparatus and instruments for the diagnosis, prevention and treatment of skin disorders; medical apparatus and instruments for use in urology; medical apparatus and instruments for ophthalmological use; medical apparatus and instruments for the diagnosis, prevention and treatment of cancer and tumors; medical apparatus and instruments for the diagnosis, prevention and treatment of allergies; medical apparatus and instruments for the diagnosis, prevention and treatment of bone diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of respiratory diseases and asthma; radiological apparatus and instruments for medical use in the nature of radiological apparatus for medical purposes; genetic testing apparatus and instruments for medical use in the nature of genetic testing apparatus for medical purposes; electromagnetic drug delivery apparatus and instruments for medical use in the nature of electromagnetic drug delivery apparatus for medical use; medical apparatus and instruments for diagnostic radiopharmaceutical use; medical apparatus and instruments for facilitating the inhalation of pharmaceutical preparations in the nature of medical apparatus for facilitating the inhalation of pharmaceutical preparations; apparatus and instruments for DNA and RNA testing for medical use in the nature of apparatus for DNA and RNA testing for medical purposes; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus and instruments for introducing pharmaceutical preparations into the human body in the nature of medical apparatus for introducing pharmaceutical preparations into the human body | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 28, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 4, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 4, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 25, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 25, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 25, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 7, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 7, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 7, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 18, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 18, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 18, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 9, 2023 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Jan 3, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 7, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 7, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 7, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 25, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 25, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 25, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 25, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 25, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 25, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 1, 2022 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Sep 27, 2022 | RFNP | REFUSAL PROCESSED BY IB | — |
| Sep 1, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 31, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 3, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 2, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 2, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| May 17, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 12, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 10, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| May 5, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |